Citius Oncology, Inc. (CTOR) Stock Overview
Explore Citius Oncology, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Citius Oncology, Inc. (CTOR)
Key Financials
Key Financials
Market Cap
53M
P/E Ratio
-1.23
EPS (TTM)
$-0.47
ROE
-0.99%
CTOR Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Citius Oncology, Inc. (CTOR) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 34.19, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.23 and a market capitalization of 53M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.